FDG-PET/MRI in Patients with Pelvic Recurrence of Rectal Cancer: First Clinical Experiences

Overview

Journal Eur Radiol

Specialty Radiology

Date 2018 Jul 8

PMID 29980927

Citations 18

Authors

Verena Plodeck

Nuh N Rahbari

Juergen Weitz

Christoph G Radosa

Michael Laniado

Ralf-Thorsten Hoffmann

Klaus Zophel

Bettina Beuthien-Baumann

Joerg Kotzerke

Joerg van den Hoff

Ivan Platzek

Affiliations

Soon will be listed here.

Abstract

Objectives: To determine the value of F-FDG-PET/MRI in the diagnosis and management of patients with pelvic recurrence of rectal cancer.

Methods: Forty-four patients (16 women, 28 men) with a history of rectal cancer who received FDG-PET/MRI between June 2011 and February 2017 at our institution were retrospectively enrolled. Three patients received two FDG-PET/MRIs; thus a total of 47 examinations were included. Pelvic recurrence was confirmed either with histology (n = 27) or imaging follow-up (n = 17) (> 4 months). Two readers (one radiologist, one nuclear medicine physician) interpreted the images in consensus. Pelvic lesions were assessed regarding FDG uptake and morphology. Sensitivity, specificity, positive and negative predictive values as well as accuracy of PET/MRI in detecting recurrence were determined.

Results: In 47 FDG-PET/MRIs 30 suspicious pelvic lesions were identified, 29 of which were malignant. Two patients underwent resection and had histologically proven pelvic recurrence without showing suspicious findings on FDG-PET/MRI. Changes in management due to FDG-PET/MRI findings had been implemented in eight patients. Eighty per cent (16/20) of resected patients had histologically negative resection margins (R0), one patient had uncertain resection margins. Sensitivity of FDG-PET/MRI in detecting recurrence was 94%, specificity 94%, positive/negative predictive value and accuracy were 97%, 90% and 94%, respectively.

Conclusions: FDG-PET/MRI is a valuable tool in the diagnosis and staging of pelvic recurrence in patients with rectal cancer.

Key Points: • Metabolic information obtained from PET coupled with excellent soft tissue contrast from MRI could facilitate detection of rectal cancer recurrence and assist in treatment planning. • PET/MRI demonstrates high sensitivity and specificity for the diagnosis of local recurrence of rectal cancer • PET/MRI led to alterations in management in 18.2% of patients.

Citing Articles

FDG-PET/MRI in colorectal cancer care: an updated systematic review.

Lo H, Choy K, Kong J Abdom Radiol (NY). 2024; 50(1):49-63.

PMID: 39073608 PMC: 11711575. DOI: 10.1007/s00261-024-04460-z.

[Treatment strategies for recurrent rectal cancer].

Dietz S, Fritzmann J, Weidlich A, Schaser K, Weitz J, Kirchberg J Chirurgie (Heidelb). 2024; 95(6):495-509.

PMID: 38739162 DOI: 10.1007/s00104-024-02087-w.

Imaging in the era of risk-adapted treatment in colon cancer.

Lahaye M, Lambregts D, Aalbers A, Snaebjornsson P, Beets-Tan R, Kok N Br J Radiol. 2024; 97(1159):1214-1221.

PMID: 38648743 PMC: 11186558. DOI: 10.1093/bjr/tqae061.

PET/MRI in colorectal and anal cancers: an update.

Jayaprakasam V, Ince S, Suman G, Nepal P, Hope T, Paspulati R Abdom Radiol (NY). 2023; 48(12):3558-3583.

PMID: 37062021 DOI: 10.1007/s00261-023-03897-y.

Surveillance strategies following curative resection and non-operative approach of rectal cancer: How and how long? Review of current recommendations.

Lauretta A, Montori G, Guerrini G World J Gastrointest Surg. 2023; 15(2):177-192.

PMID: 36896297 PMC: 9988648. DOI: 10.4240/wjgs.v15.i2.177.

References

Flamen P, Stroobants S, Van Cutsem E, Dupont P, Bormans G, De Vadder N . Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol. 1999; 17(3):894-901. DOI: 10.1200/JCO.1999.17.3.894. View

Law W, Chu K, Choi H . Total pelvic exenteration for locally advanced rectal cancer. J Am Coll Surg. 2000; 190(1):78-83. DOI: 10.1016/s1072-7515(99)00229-x. View

Berger K, Nicholson S, Dehdashti F, Siegel B . FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol. 2000; 174(4):1005-8. DOI: 10.2214/ajr.174.4.1741005. View

Imdahl A, Reinhardt M, Nitzsche E, Mix M, Dingeldey A, Einert A . Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences. Langenbecks Arch Surg. 2000; 385(2):129-34. DOI: 10.1007/s004230050255. View

Huebner R, Park K, Shepherd J, SCHWIMMER J, Czernin J, Phelps M . A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med. 2000; 41(7):1177-89. View

Imbriaco , Akhurst , HILTON , Yeung , Macapinlac , Mazumdar . Whole-Body FDG-PET in Patients with Recurrent Colorectal Carcinoma. A Comparative Study with CT. Clin Positron Imaging. 2000; 3(3):107-114. DOI: 10.1016/s1095-0397(00)00045-5. View

Huguier M, Houry S, Barrier A . Local recurrence of cancer of the rectum. Am J Surg. 2002; 182(5):437-9. DOI: 10.1016/s0002-9610(01)00748-6. View

Yamada K, Ishizawa T, Niwa K, Chuman Y, Aikou T . Pelvic exenteration and sacral resection for locally advanced primary and recurrent rectal cancer. Dis Colon Rectum. 2002; 45(8):1078-84. DOI: 10.1007/s10350-004-6363-1. View

Moore H, Akhurst T, Larson S, Minsky B, Mazumdar M, Guillem J . A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients. J Am Coll Surg. 2003; 197(1):22-8. DOI: 10.1016/S1072-7515(03)00337-5. View

10.

Lerman H, Metser U, Grisaru D, Fishman A, Lievshitz G, Even-Sapir E . Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med. 2004; 45(2):266-71. View

11.

Even-Sapir E, Parag Y, Lerman H, Gutman M, Levine C, Rabau M . Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology. 2004; 232(3):815-22. DOI: 10.1148/radiol.2323031065. View

12.

Arriola E, Navarro M, Pares D, Munoz M, Pareja L, Figueras J . Imaging techniques contribute to increased surgical rescue of relapse in the follow-up of colorectal cancer. Dis Colon Rectum. 2006; 49(4):478-84. DOI: 10.1007/s10350-005-0280-9. View

13.

Titu L, Nicholson A, Hartley J, Breen D, Monson J . Routine follow-up by magnetic resonance imaging does not improve detection of resectable local recurrences from colorectal cancer. Ann Surg. 2006; 243(3):348-52. PMC: 1448927. DOI: 10.1097/01.sla.0000201454.20253.07. View

14.

Abir F, Alva S, Longo W, Audiso R, Virgo K, Johnson F . The postoperative surveillance of patients with colon cancer and rectal cancer. Am J Surg. 2006; 192(1):100-8. DOI: 10.1016/j.amjsurg.2006.01.053. View

15.

Ito K, Kato T, Tadokoro M, Ishiguchi T, Oshima M, Ishigaki T . Recurrent rectal cancer and scar: differentiation with PET and MR imaging. Radiology. 1992; 182(2):549-52. DOI: 10.1148/radiology.182.2.1732979. View

16.

Schaefer O, Langer M . Detection of recurrent rectal cancer with CT, MRI and PET/CT. Eur Radiol. 2007; 17(8):2044-54. DOI: 10.1007/s00330-007-0613-2. View

17.

Sebag-Montefiore D, Stephens R, Steele R, Monson J, Grieve R, Khanna S . Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009; 373(9666):811-20. PMC: 2668947. DOI: 10.1016/S0140-6736(09)60484-0. View

18.

Boellaard R, ODoherty M, Weber W, Mottaghy F, Lonsdale M, Stroobants S . FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2009; 37(1):181-200. PMC: 2791475. DOI: 10.1007/s00259-009-1297-4. View

19.

Rahbari N, Ulrich A, Bruckner T, Munter M, Nickles A, Contin P . Surgery for locally recurrent rectal cancer in the era of total mesorectal excision: is there still a chance for cure?. Ann Surg. 2011; 253(3):522-33. DOI: 10.1097/SLA.0b013e3182096d4f. View

20.

Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2011; 127(12):2893-917. DOI: 10.1002/ijc.25516. View